Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen 1Q

TECFIDERA revenues up 63%

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen
 
1Q Revenues: $2.6 billion (+20%)

1Q Earnings: $823 million (+71%)

Comments: Total multiple sclerosis product sales were $2.1 billion compared to $1.7 billion in 1Q14. TECFIDERA revenues were $825 million, up 63%. Interferon revenues, including AVONEX and PLEGRIDY, were flat at $755 million. TYSABRI revenues were $463 million, up 5%. Revenues relating to RITUXAN and GAZYVA from Biogen’s unconsolidated joint business arrangement were $331 million, up 11%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters